Reforming ANDA Suitability Petitions
Pharmaceutical companies have faced delays in receiving a response to their Suitability Petitions by the United States Food and Drugs Administration (US FDA). This has been a problem as delay in responses have led to the delay of Abbreviated New Drug Applications (ANDA) entering the market. The US FDA has committed to proactively reviewing the […]
Reforming ANDA Suitability Petitions Read More »